keyword
MENU ▼
Read by QxMD icon Read
search

Wearable Defibrillator

keyword
https://www.readbyqxmd.com/read/28499628/a-real-world-wearable-cardioverter-defibrillator-experience-very-high-appropriate-shock-rate-in-ischemic-cardiomyopathy-patients-at-a-european-single-center
#1
Thomas Beiert, Robert Malotki, Natalie Kraemer, Florian Stöckigt, Markus Linhart, Georg Nickenig, Jan W Schrickel, René P Andrié
BACKGROUND: The wearable cardioverter defibrillator (WCD) has emerged as a valuable tool to protect patients with increased risk of sudden cardiac death (SCD). We sought to characterize WCD patients and to analyze predictors of ventricular arrhythmia (VA) occurrence and WCD shock delivery. METHODS AND RESULTS: One hundred fourteen patients with WCD use were included in the study. Indications were mainly ischemic cardiomyopathy (ICM; 31.6%), non-ICM (45.6%) and explantation of implantable cardioverter defibrillator due to device infection (11...
April 28, 2017: Journal of Electrocardiology
https://www.readbyqxmd.com/read/28454824/the-impact-of-body-mass-index-on-the-wearable-cardioverter-defibrillator-shock-efficacy-and-patient-wear-time
#2
Chingping Wan, Steven J Szymkiewicz, Helmut U Klein
BACKGROUND: The impact of body mass index (BMI) on the shock efficacy and patient adherence among patients using a wearable cardioverter defibrillator (WCD) is unknown. METHODS: Patients prescribed the WCD between January 1, 2008 and June 1, 2013, who experienced at least one episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and who received appropriate WCD therapy, were identified within a registry maintained by the manufacturer for regulatory, reimbursement, and administrative purposes...
April 2017: American Heart Journal
https://www.readbyqxmd.com/read/28429542/study-of-the-wearable-cardioverter-defibrillator-in-advanced-heart-failure-patients-swift
#3
Alon Barsheshet, Valentina Kutyifa, Theodora Vamvouris, Arthur J Moss, Yitschak Biton, Leway Chen, Eugene Storozynsky, Chingping Wan, Steven J Szymkiewicz, Ilan Goldenberg
INTRODUCTION: The wearable cardioverter defibrillator (WCD) may allow stabilization until reassessment for an implantable cardioverter defibrillator (ICD) among high-risk HF patients. However, there are limited data on the WCD benefit in the acute decompensated HF setting. METHODS AND RESULTS: The Study of the Wearable Cardioverter Defibrillator in Advanced Heart-Failure Patients (SWIFT) was a prospective clinical trial carried out at two medical centers. Patients hospitalized with advanced HF symptoms and reduced left ventricular ejection function (LVEF) were enrolled and prescribed a WCD prior to discharge for a total of 3 months...
April 21, 2017: Journal of Cardiovascular Electrophysiology
https://www.readbyqxmd.com/read/28409333/the-wearable-defibrillator-a%C3%A2-most-affordable-vest
#4
EDITORIAL
J R de Groot
No abstract text is available yet for this article.
May 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28333373/ventricular-arrhythmias-in-patients-with-newly-diagnosed-nonischemic-cardiomyopathy-insights-from-the-prolong-study
#5
David Duncker, Thorben König, Stephan Hohmann, Johann Bauersachs, Christian Veltmann
BACKGROUND: Patients with nonischemic cardiomyopathy (NICM) reportedly have low incidence of appropriate shocks from wearable cardioverter-defibrillators (WCDs). A recent study questions the benefit from primary preventive implantation of implantable cardioverter-defibrillators in NICM. We therefore analyzed a subgroup of patients with NICM from the PROLONG study. HYPOTHESIS: Patients with newly diagnosed NICM show a risk for ventricular tachyarrhythmia. METHODS: The PROLONG study included 167 patients with newly diagnosed heart failure and left ventricular ejection fraction (LVEF) ≤35% with a WCD...
March 23, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28275862/risk-for-life-threatening-arrhythmia-in-newly-diagnosed-peripartum-cardiomyopathy-with-low-ejection-fraction-a-german-multi-centre-analysis
#6
David Duncker, Ralf Westenfeld, Torsten Konrad, Tobias Pfeffer, Carlos A Correia de Freitas, Roman Pfister, Dierk Thomas, Alexander Fürnkranz, René P Andrié, Andreas Napp, Jörn Schmitt, Laszlo Karolyi, Reza Wakili, Denise Hilfiker-Kleiner, Johann Bauersachs, Christian Veltmann
INTRODUCTION: Peripartum cardiomyopathy (PPCM) is a rare cardiomyopathy characterized by an acute reduction in left ventricular ejection fraction (LVEF). Sudden deaths during the course of PPCM are reported to be elevated, the underlying mechanisms remains unknown. The aim of the present multi-centre study was to evaluate the arrhythmia burden in a multi-centre approach in patients with PPCM using a wearable cardioverter/defibrillator (WCD). METHODS AND RESULTS: Forty-nine patients from 16 German centres with newly diagnosed PPCM and LVEF ≤35% receiving a WCD were included in this retrospective analysis...
March 8, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/28188473/outpatient-treatment-with-the-wearable-cardioverter-defibrillator-clinical-experience-in-two-dutch-centres
#7
A F B E Quast, V F van Dijk, A A M Wilde, R E Knops, L V A Boersma
INTRODUCTION: The latest European Society of Cardiology Guidelines recommend consideration of a wearable cardioverter-defibrillator (WCD) for patients with a poor left ventricular ejection fraction (LVEF) who are at risk of sudden arrhythmic death but are not eligible for an implantable defibrillator. For these patients a WCD can be an alternative to long-term hospitalisation. PURPOSE: To evaluate the use of WCD therapy in these patient groups in two Dutch centres...
May 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28182235/a-wearable-defibrillator-life-vest
#8
A Tofield
No abstract text is available yet for this article.
January 21, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28182226/indications-and-use-of-the-wearable-cardiac-defibrillator
#9
Parikshit S Sharma, Pierre Bordachar, Kenneth A Ellenbogen
No abstract text is available yet for this article.
January 21, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28096098/avoiding-untimely-implantable-cardioverter-defibrillator-implantation-by-intensified-heart-failure-therapy-optimization-supported-by-the-wearable-cardioverter-defibrillator-the-prolong-study
#10
David Duncker, Thorben König, Stephan Hohmann, Johann Bauersachs, Christian Veltmann
BACKGROUND: Optimal timing of implantation of an implantable cardioverter/defibrillator (ICD) after newly diagnosed heart failure is unclear given that late reverse remodelling may occur. We aimed to analyze left ventricular ejection fraction (LVEF) after diagnosis of an LVEF ≤35% during optimization of heart failure drug therapy. METHODS AND RESULTS: One hundred fifty-six patients with newly diagnosed LVEF ≤35% receiving a wearable cardioverter/defibrillator (WCD) were analyzed...
January 17, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27943296/safety-of-the-wearable-cardioverter-defibrillator-wcd-in-patients-with-implanted-pacemakers
#11
Joern Schmitt, Guezine Abaci, Victoria Johnson, Damir Erkapic, Christopher Gemein, Ritvan Chasan, Kay Weipert, Christian W Hamm, Helmut U Klein
BACKGROUND: The wearable cardioverter defibrillator (WCD) is an important approach for better risk stratification, applied to patients considered to be at high risk of sudden arrhythmic death. Patients with implanted pacemakers may also become candidates for use of the WCD. However, there is a potential risk that pacemaker signals may mislead the WCD detection algorithm and cause inappropriate WCD shock delivery. The aim of the study was to test the impact of different types of pacing, various right ventricular (RV) lead positions, and pacing modes for potential misleading of the WCD detection algorithm...
March 2017: Pacing and Clinical Electrophysiology: PACE
https://www.readbyqxmd.com/read/27920335/prevention-of-sudden-cardiac-death-by-the-wearable-cardioverter-defibrillator-in-a-young-patient-with-cardiac-sarcoidosis
#12
René Andrié, Florian C Gaertner, Dirk Skowasch
No abstract text is available yet for this article.
March 2017: Thorax
https://www.readbyqxmd.com/read/27909495/the-wearable-cardioverter-defibrillator-toy-or-tool
#13
REVIEW
David Duncker Md, Christian Veltmann Md
After the success story of implantable cardioverter/defibrillator systems, prevention of sudden cardiac death (SCD) remains one of the main duties in cardiology. For patients with unkown or transient risk profile for SCD, a wearable cardioverter/defibrillator (WCD) has been established for temporary and effective prevention of sudden arrhythmic death. Several studies have shown safety and efficacy of the WCD, even though randomized studies proving a mortality benefit are still lacking. This review provides an overview of actual WCD data and usage, special indications and possible risks and complications...
April 2016: Journal of Atrial Fibrillation
https://www.readbyqxmd.com/read/27909469/value-of-the-wearable-cardioverter-defibrillator-wcd-as-a-bridging-therapy-before-implantation-of-a-cardioverter-defibrillator-icd
#14
REVIEW
Priv Doz, Johannes Sperzel
Wearable cardioverter defibrillators (WCD), initially available in 2002, have recently experienced more routine use in many institutions as a means of preventing sudden cardiac death (SCD) prior to implantable cardioverter defibrillator (ICD) evaluation or implantation. WCD differ from ICD by their noninvasive nature, making them well suited for patient populations who have a chance for significant cardiac recovery (such as after an acute myocardial infarction). Despite their noninvasive nature, WCD treatment of sustained ventricular tachyarrhythmias is highly successful...
February 2016: Journal of Atrial Fibrillation
https://www.readbyqxmd.com/read/27889844/long-term-use-of-the-wearable-cardioverter-defibrillator-prolonging-life-or-prolonging-indecision
#15
EDITORIAL
Evan Adelstein
No abstract text is available yet for this article.
January 2017: Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing
https://www.readbyqxmd.com/read/27888304/the-wearable-cardioverter-defibrillator-in-a-real-world-clinical-setting-experience-in-102-consecutive-patients
#16
Julia W Erath, Mate Vamos, Abdul Sami Sirat, Stefan H Hohnloser
BACKGROUND: The wearable cardioverter-defibrillator (WCD) is used for temporary protection of patients deemed to be at high risk for sudden death (SCD) not yet meeting indications for the implantable defibrillator (ICD). OBJECTIVES: To evaluate the efficacy, safety, and compliance of/to WCD use and subsequent medium-term outcome of patients in a single-center observational study. METHODS: A total of 102 consecutive patients were fitted with the WCD from 2012 to 2015 and followed for a mean of 11 months (±8 months)...
April 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/27799257/defibrillators-selecting-the-right-device-for-the-right-patient
#17
REVIEW
Sana M Al-Khatib, Paul Friedman, Kenneth A Ellenbogen
Advances in the field of defibrillation have brought to practice different types of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or without cardiac resynchronization therapy, the subcutaneous ICD (S-ICD), and the wearable cardioverter-defibrillator. To ensure optimal use of these devices and to achieve best patient outcomes, clinicians need to understand how these devices work, learn the characteristics of patients who qualify them for one type of device versus another, and recognize the remaining gaps in knowledge surrounding these devices...
November 1, 2016: Circulation
https://www.readbyqxmd.com/read/27755136/the-wearable-defibrillator-current-technology-indications-and-future-directions
#18
Sven Reek
PURPOSE OF REVIEW: The wearable cardioverter-defibrillator has been available for over a decade. In recent years, the device has been prescribed increasingly for a wide range of indications. The purpose of this review is to describe the technical and clinical aspects of the wearable cardioverter-defibrillator. The available literature on safety, efficacy and cost-effectiveness is reviewed, and indications for use will be discussed. RECENT FINDINGS: The wearable cardioverter-defibrillator has been used successfully in more than 100 000 patients for a variety of indications...
January 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27752809/national-experience-with-long-term-use-of-the-wearable-cardioverter-defibrillator-in-patients-with-cardiomyopathy
#19
Madhab Lamichhane, Joseph C Gardiner, Nicole R Bianco, Steven J Szymkiewicz, Ranjan K Thakur
PURPOSE: The wearable cardioverter defibrillator (WCD) is generally used for short periods of sudden cardiac death (SCD) risk; circumstances may occasionally result in prolonged use (over 1 year). The aim of this study was to determine the benefits and risks of prolonged use in patients with systolic heart failure (HF). METHODS: ZOLL's post-market US database included adult patients (≥18 years) with ischemic and/or non-ischemic cardiomyopathy (ICM, NICM) and at least 1 year of use...
January 2017: Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing
https://www.readbyqxmd.com/read/27702851/the-wearable-cardioverter-defibrillator-current-technology-and-evolving-indications
#20
Sven Reek, Haran Burri, Paul R Roberts, Christian Perings, Andrew E Epstein, Helmut U Klein, Gregory Lip, Bulent Gorenek, Christian Sticherling, Laurent Fauchier, Andreas Goette, Werner Jung, Marc A Vos, Michele Brignole, Christian Elsner, Gheorghe-Andrei Dan, Francisco Marin, Giuseppe Boriani, Deirdre Lane, Carina Blomstrom Lundqvist, Irina Savelieva
The wearable cardioverter-defibrillator has been available for over a decade and now is frequently prescribed for patients deemed at high arrhythmic risk in whom the underlying pathology is potentially reversible or who are awaiting an implantable cardioverter-defibrillator. The use of the wearable cardioverter-defibrillator is included in the new 2015 ESC guidelines for the management of ventricular arrhythmias and prevention of sudden cardiac death. The present review provides insight into the current technology and an overview of this approach...
March 1, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
keyword
keyword
86356
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"